Artivion (AORT) Short-Term Debt repayments (2023 - 2026)

Artivion (AORT) reported Short-Term Debt repayments of $577000.0 for Q1 2026, down 32.51% quarter-over-quarter from $855000.0 in Q4 2025.

Artivion (AORT) Short-Term Debt repayments (2023 - 2026) Analysis & Trends

Artivion has reported Short-Term Debt repayments for 4 years, with the latest figure at $577000.0 in Q1 2026.

For the quarter ending Q1 2026, Short-Term Debt repayments changed N/A year-over-year to $577000.0; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (changed N/A YoY), and the FY2025 full-year result was $2.2 million, up 119.08% from the prior year.
Short-Term Debt repayments for Q1 2026 stood at $577000.0, down from $855000.0 in the prior quarter.
The five-year high for Short-Term Debt repayments was $1.0 million in Q1 2024, with the low at $529000.0 in Q2 2023.
Historically, Short-Term Debt repayments has averaged $798125.0 across 4 years, with a median of $848000.0 in 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Short-Term Debt repayments (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn	-
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn	-
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn	-
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn	259.00 Mn
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn	-
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn	-
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	-
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn	-
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn	-
10	Artivion	963.64 Mn	907.88 Mn	75.45 Mn	577,000.00

Download Data